Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-899-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In vivo (GPMT): not sensitising
Human data (RIPT): not sensitising
Read-across from structural analogue source substance 2,2-bis[[(1-oxoisooctadecyl)oxy]methyl]-1,3-propanediyl bis(isooctadecanoate) (CAS 62125-22-8)
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 Nov - 23 Dec 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- adopted Jul 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- The Department of Health of the Government if the United Kingdom
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- A non-LLNA test is available that was performed prior to the current data requirements, stipulated in Regulation (EC) No 1907/2006. In accordance with the same Regulation, the data was included to avoid unnecessary testing.
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: David Hall Limited, Staffordshire, UK
- Age at study initiation: 8 -12 weeks
- Weight at study initiation: 332 - 383 g (range)
- Housing: The animals were housed singly or in pairs in solid-floor polyporpylene cages furnished with woodflakes.
- Diet: Guinea Pig FD1 Diet (Special Diets Services Limited, Essex, UK), ad libitum
- Water: Tap water, ad libitum
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17 - 23
- Humidity (%): 30 - 70
- Air changes (per hr): Approximately 15
- Photoperiod (hrs dark / hrs light): 12/12
- IN-LIFE DATES: From: 15 Nov 1999 To: 23 Dec 1999 - Route:
- intradermal
- Vehicle:
- arachis oil
- Concentration / amount:
- 1% (w/w)
- Day(s)/duration:
- Single injection on Day 1
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- Route:
- epicutaneous, occlusive
- Vehicle:
- arachis oil
- Concentration / amount:
- 25% (w/w)
- Day(s)/duration:
- Applied on Day 7, 48 h
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- No.:
- #1
- Route:
- epicutaneous, open
- Vehicle:
- arachis oil
- Concentration / amount:
- 10 and 25% (w/w)
- Day(s)/duration:
- Applied on Day 21, 24 h
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- 10 (test groups), 5 (controls)
- Details on study design:
- RANGE FINDING TESTS: To determine a suitable concentration for the intradermal induction in the main study, 2 concentrations of the test substance (1 and 5% w/w) in arachis oil BP were selected. A total of 2 female guinea pigs each received 4 injections of 0.1 mL of one concentration only. The degree of erythema at the injection sites was recorded approximately 24, 48 and 72 h, and 7 days after injection. Clinical signs of systemic toxicity were also recorded. A concentration of 5% w/w in arachis oil BP induced erythema (grade 1) after seven days, therefore a concentration of 1% w/w was selected for the intradermal induction stage of the main study. To determine a suitable concentration for the epicutaneous induction in the main study, 2 females were intradermal injected with Freund's Complete Adjuvant on Day 0, and then each treated by epicutaneous application with 5, 10, 25 and 50% w/w of the test substance in arachis oil BP. The test substance was applied to the clipped flanks of the animals under occlusive dressings for 48 hours, and the degree of erythema and oedema was assessed approximately 1, 24 and 48 h after patch removal. A concentration of 50% w/w in arachis oil BP induced erythema (grade 2) and edema (grade 1) after 48 h, therefore a concentration of 25% w/w was selected for the epicutaneous induction stage of the main study.
To determine a suitable concentration for the epicutaneous challenge in the main study, 2 females were treated by epicutaneous application with 5, 10, 25 and 50% w/w of the test substance in arachis oil BP. The test substance was applied to the clipped flanks of the animals under occlusive dressings for 48 hours, and the degree of erythema and oedema was assessed approximately 1, 24 and 48 h after patch removal. The concentrations of the test material selected for the main study topical challenge were 25 and 10% w/w in arachis oil BP.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single injection (intradermal) and 48 h (epicutaneous)
- Test groups:
Intradermal (3 pairs of injections):
Injection 1: a 1:1 mixture v/v FCA/water
Injection 2: a 1% w/w formulation of the test substance in arachis oil BP
Injection 3: a 1% w/w formulation of the test material in a 1:1 mixture v/v FCA/water
Epicutaneous: 25% w/w of the test substance in arachis oil BP
- Control group:
Intradermal (3 pairs of injections):
Injection 1: a 1:1 mixture v/v FCA/water
Injection 2: arachis oil BP
Injection 3: a 50% w/w formulation of arachis oil BP in a 1:1 mixture v/v FCA/water
Epicutaneous: blank patch
- Site: shoulder region (intradermal and epicutaneous)
- Frequency of applications: Day 0 (intradermal) and Day 7 (epicutaneous)
- Duration: Days 0 - 7
- Concentrations: intradermal 1% w/w, epicutaneous 25% w/w
B. CHALLENGE EXPOSURE
- No. of exposures: 1 (challenge)
- Day(s) of challenge: 21
- Exposure period: 24 h
- Test groups: test substance in arachis oil BP
- Site: right flank (25% w/w), left flank (10% w/w)
- Concentrations: 10 and 25% w/w
- Evaluation (hr after challenge): 25 and 48 h after patch removal
OTHER: Approximately 24 and 48 h after intradermal injection the degree of erythema at the injection sites was evaluated. The degree of erythema and oedema was assessed approximately 1 and 24 h after patch removal following the topical induction. Any evidence of systemic toxicity was recorded. The bodyweight of each animal was recorded at the start and end of the study. - Positive control substance(s):
- yes
- Positive control results:
- Reliability checks were performed at least every 6 months at the testing laboratory to assess the sensitivity and reliability of the test method. A summary of the studies performed from Dec 1996 to Jul 1999 under same experimental conditions was included in the study report. The animals were administered 2-mercaptobenzothiazole. A response of 70-100% of the animals was observed in all the reliability checks. Therefore the positive control is considered to be valid.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- Induction: 1% (intradermal), 25% (epicutaneous); challenge: 10 and 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No local skin irritation reactions and no signs of systemic toxicity were observed
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- Induction: 1% (intradermal), 25% (epicutaneous); challenge: 10 and 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No local skin irritation reactions and no signs of systemic toxicity were observed
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- Induction: arachis oil (intradermal), arachis oil (epicutaneous); challenge: 10 and 25%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No local skin irritation reactions and no signs of systemic toxicity were observed
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- Induction: arachis oil (intradermal), arachis oil (epicutaneous); challenge: 10 and 25%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No local skin irritation reactions and no signs of systemic toxicity were observed
- Key result
- Group:
- positive control
- Remarks on result:
- positive indication of skin sensitisation
- Interpretation of results:
- other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No. 1272/2008
- Conclusions:
- CLP: not classified
Reference
Following the intradermal induction, discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) were observed at the injection sites of 10/10 treatment animals (1% test material in arachis oil) and discrete or patchy erythema (grade 1) were noted in 4/5 control animals (arachis oil), both at the 24-hour reading time point. At the 48-hour reading time point, in 10/10 treatment animals discrete or patchy erythema (grade 1), moderate to confluent erythema (grade 2) or intense erythema and swelling (grade 3) and in 4/5 control animal discrete or patchy erythema (grade 1) were observed, respectively. Following the topical induction (25% in arachis oil BP), discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) were observed at the application site in 10/10 treatment animals at the one-hour reading time point and at the 24-hour reading time point. Bleeding from the intradermal induction site was noted in 9/10 treatment animals at the one-hour reading time point following the topical induction, while hardened dark brown/black coloured scabs were noted at the topical induction sites in 1/10 treatment animals at the 24-hour observation time point. 3/5 control animals at the one-hour reading time point and 2/5 animals at the 24-hour reading time point showed discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) following the topical induction, moreover, bleeding from the intradermal induction site was noted in 2/5 control animals at the one-hour reading time point, while hardened dark brown/black coloured scabs were noted at the topical induction sites in 1/5 control animals at the 24-hour observation time point.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Data on skin sensitisation of the target substance fatty acids C18-C22 (even numbered), tetraesters with pentaerythritol are available. Moreover, human data on skin sensitisation conducted with the source substance 2,2-bis[[(1-oxoisooctadecyl)oxy]methyl]-1,3-propanediyl (CAS 62125-22-8) were also taken into account for the hazard evaluation.
A guinea pig maximisation test was performed with fatty acids C18-C22 (even numbered), tetraesters with pentaerythritol according to OECD 406 and under GLP conditions (Safepharm Laboratories, 2000). A range-finding study was performed to establish suitable dose levels for the induction and challenge treatments. In the main study, 10 female Dunkin-Hartley guinea pigs were induced intradermally on Day 0 with 3 pairs of injections: with a 1:1 mixture Freund’s Complete Adjuvant (FCA)/water, with 1% test substance in arachis oil BP and with 1% test substance in a 1:1 mixture FCA/water. On day 7, 25% test substance in arachis oil BP in a 1:1 mixture FCA/water was applied to the skin of the animals for 48 hours. On Day 21, the challenge treatment was performed by topical application of 10 and 25% test substance dilution for 24 hours. Five animals served as negative controls and were exposed to the vehicle only. Reliability checks were performed with 2-mercaptobenzothiazole under the same experimental conditions and indicated the reliability and sensitivity of the study. Following the intradermal induction, discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) were observed at the injection sites of 10/10 treatment animals (1% test material in arachis oil) and discrete or patchy erythema (grade 1) were noted in 4/5 control animals (arachis oil), both at the 24-hour reading time point. At the 48-hour reading time point, in 10/10 treatment animals discrete or patchy erythema (grade 1), moderate to confluent erythema (grade 2) or intense erythema and swelling (grade 3) and in 4/5 control animal discrete or patchy erythema (grade 1) were observed, respectively. Following the topical induction (25% in arachis oil BP), discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) were observed at the application site in 10/10 treatment animals at the one-hour reading time point and at the 24-hour reading time point. Bleeding from the intradermal induction site was noted in 9/10 treatment animals at the one-hour reading time point following the topical induction, while hardened dark brown/black coloured scabs were noted at the topical induction sites in 1/10 treatment animals at the 24-hour observation time point. 3/5 control animals at the one-hour reading time point and 2/5 animals at the 24-hour reading time point showed discrete or patchy erythema (grade 1) or moderate to confluent erythema (grade 2) following the topical induction, moreover, bleeding from the intradermal induction site was noted in 2/5 control animals at the one-hour reading time point, while hardened dark brown/black coloured scabs were noted at the topical induction sites in 1/5 control animals at the 24-hour observation time point.
0/10 treatment animals and 0/5 control animals showed skin reactions 24 and 48 h after the challenge treatment, indicating that the test substance did not cause skin sensitisation. Under the conditions of this test the test substance is considered to be not sensitising to guinea pigs.
CAS 62125-22-8
A repeated insult human patch test (RIPT) was conducted to assess the sensitizing potential of 2,2-bis[[(1-oxoisooctadecyl)oxy]methyl]-1,3-propanediyl (CAS 62125-22-8) in 55 human volunteers from the general population (CPTC, 1985). Induction was carried out by 10 repeated semiocclusive applications of the unchanged test substance. Patches were placed on the back of volunteers for 24 hours, followed by a 24 hour rest period (48 hours on weekends). The 10 induction patches were applied to the same site. The induction phase was followed by a resting period of 14 days. Challenge patches were applied to the same site on the back and to a naïve site. Skin reactions were assessed 24 and 48 hours after patch removal. None of the human volunteers showed any skin reactions at the end of the study period. Thus, the test material is not considered sensitising to humans.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available data on in vivo skin sensitisation with the target substance fatty acids C18-C22 (even numbered), tetraesters with pentaerythritol and the available data on skin sensitisation in humans with the source substance 2,2-bis[[(1-oxoisooctadecyl)oxy]methyl]-1,3-propanediyl (CAS 62125-22-8) do not meet the classification criteria according to Regulation (EC) No 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.